Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 132 Carcinoma, Transitional Cell 92 Carcinoma, Non-Small-Cell Lung 84 Urinary Bladder Neoplasms 81 Melanoma 75 Squamous Cell Carcinoma of Head and Neck 50 Prostatic Neoplasms 49 Colorectal Neoplasms 41 Ovarian Neoplasms 36 Stomach Neoplasms 35 Triple Negative Breast Neoplasms 33 Neoplasm Metastasis 32 Uterine Cervical Neoplasms 31 Neoplasms 28 Kidney Neoplasms 27 Breast Neoplasms 27 Parkinson Disease 4, Autosomal Dominant Lewy Body 26 Lung Neoplasms 26 Pancreatic Neoplasms 23 Carcinoma, Hepatocellular 23 Esophageal Neoplasms 21 Head and Neck Neoplasms 20 Endometrial Neoplasms 18 Small Cell Lung Carcinoma 16 Carcinoma, Merkel Cell 11 Mesothelioma 9 Cholangiocarcinoma 9 Ureteral Neoplasms 8 Sarcoma 8 Carcinoma, Ovarian Epithelial 8

Interventions

zimberelimab 1 sacituzumab govitecan 1 pembrolizumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Urothelial Bladder Carcinoma × pembrolizumab × Genitourinary × Clear all

NCT02736266 2023-07-18

PURE-01

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano

Phase 2 Completed

Urothelial Bladder Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡